ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs
Growth Capitalist (https://growthcapitalist.com/2018/06/significant-blood-sugar-improvement-with-xultophy-100-3-6-compared-to-insulin-glargine-u-100-when-used-as-add-on-to-oral-diabetes-medications/)
ORLANDO, Fla., June 23, 2018 /PRNewswire/ -- Xultophy® 100/3.6 (insulin degludec and liraglutide injection) 100 units/mL and 3.6 mg/mL provided superior A1C reduction compared to insulin glargine U-100 (1.94% vs